The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs are likely "weeks away," which would be later than initially promised, reported Reuters, citing official and industry sources. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

Pharma tariff announcement likely ‘weeks away,’ Reuters reports

Reuters reports that the U.S. administration, under President Donald Trump, is expected to announce the results of a probe into pharmaceutical imports and introduce new sector-specific tariffs within the next few weeks, although this timeline is later than initially anticipated. The announcement is expected to impact major publicly traded pharmaceutical companies such as AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and Sanofi.